Project Confirm: Accelerated Drug Approvals for CML-Letter
Clin Cancer Res
.
2024 Jan 5;30(1):235-236.
doi: 10.1158/1078-0432.CCR-23-2630.
Authors
Jan H Beumer
1
2
3
,
Salvatore J Salamone
4
Affiliations
1
Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
2
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
3
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh. Pittsburgh, Pennsylvania.
4
Saladax Biomedical Inc., Bethlehem, Pennsylvania.
PMID:
38178775
PMCID:
PMC10783536
(available on
2024-07-05
)
DOI:
10.1158/1078-0432.CCR-23-2630
No abstract available
Publication types
Letter
Comment
MeSH terms
Drug Approval*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
United States
United States Food and Drug Administration
Grants and funding
UM1 CA186690/CA/NCI NIH HHS/United States
P30 CA047904/CA/NCI NIH HHS/United States
U24 CA247643/CA/NCI NIH HHS/United States